Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Net Income (2017 - 2025)

Puma Biotechnology's Net Income history spans 9 years, with the latest figure at -$17.7 million for Q4 2025.

  • For Q4 2025, Net Income fell 236.45% year-over-year to -$17.7 million; the TTM value through Sep 2025 reached $30.6 million, up 31.77%, while the annual FY2024 figure was $23.9 million, 10.81% up from the prior year.
  • Net Income reached -$17.7 million in Q4 2025 per PBYI's latest filing, down from $8.8 million in the prior quarter.
  • In the past five years, Net Income ranged from a high of $20.3 million in Q3 2024 to a low of -$44.7 million in Q3 2021.
  • Average Net Income over 5 years is $824500.0, with a median of $2.6 million recorded in 2023.
  • Peak YoY movement for Net Income: soared 1710.0% in 2023, then plummeted 443.68% in 2024.
  • A 5-year view of Net Income shows it stood at $4.2 million in 2021, then plummeted by 232.77% to -$5.6 million in 2022, then skyrocketed by 318.76% to $12.3 million in 2023, then rose by 5.58% to $13.0 million in 2024, then tumbled by 236.45% to -$17.7 million in 2025.
  • Per Business Quant, the three most recent readings for PBYI's Net Income are -$17.7 million (Q4 2025), $8.8 million (Q3 2025), and $5.9 million (Q2 2025).